Geometrical Aspects of An Abelian (2,0) Action

We explore various geometrical aspects of an action for six-dimensional chiral 2-forms based on the formalism of 1903.12196. We elucidate the coupling to general backgrounds and construct the full supersymmetric completion to an abelian (2,0) superconformal lagrangian including matter. We investigate the non-standard diffeomorphism properties of the fields and their relation to the hamiltonian formulation. We also test the action by considering compactifications on a circle, K3 and a Riemann surface. The results are consistent with expectations for an action describing the low-energy physics of an M5-brane in M-theory

Aspects of (Super)Conformal Field Theories in Even dimensions

The thorough study of Conformal-Field-Theories (CFTs) and Super-Conformal Field Theories (SCFTs) lies at the heart of the towering progress that our understanding of Quantum Field Theories (QFTs) has witnessed in the last decades or so. SCFTs are admitted to exist in spacetimes with dimension no greater than six and in this thesis we closely examine some aspects of those Superconformal Field Theories (SCFTs) that live in an even dimensional spacetime. We start with the 6D (2,0) theory, which describes the low-energy dynamics of M5branes in M-theory. While in the case of multiple M5-branes, such model is believed to be inherently non-lagrangian, writing a Lagrangian that captures the low-energy dynamics of a single M5-brane is feasible but non-trivial, as one has to overcome the notorious difficulties that arise when formulating a manifestly Lorentz-invariant action for self-dual forms. Building on recent work of A. Sen, we surmount such difficulties and introduce a lagrangian formalism that enables us to elucidate how self-dual forms couple to a curved spacetime background and compute their partition function via a path integral approach. As we show in full detail for the case of the compact chiral boson on a two-dimensional torus, to evaluate their partition function via a path integral approach it is crucial to use a Wick-rotation procedure obtained from a complex deformation of the physical spacetime metric. We then move down to 4D, where we are mainly interested in the non-perturbative dynamics of SCFTs with N = 2 or N = 3 supersymmetry. In theories with N = 2 supersymmetry, one can find the so-called Coulomb-Branch Operators (CBOs), and we give strong evidence for the fact that the Type-B Weyl anomalies associated to them are covariantly constant along the conformal manifold, in both the conformal and the spontaneously broken phases. In the case of N = 3 theories, we evaluate the Macdonald limit of the superconformal index for some rank one and rank two S-fold SCFTs; we achieve this by computing the vacuum character for the two dimensional N = 2 vertex operator algebras which, via the 4D/2D correspondence, are supposed to correspond to such theories

Covariantly Constant Anomalies on Conformal Manifolds

Operators with integer scaling dimensions in even-dimensional conformal field theories exhibit well-known type-B Weyl anomalies. In general, these anomalies depend nontrivially on exactly marginal couplings. We study the corresponding fully covariantized anomaly functional on conformal manifolds in several examples. We show that a natural consequence of the Wess-Zumino consistency condition is that the anomalies are covariantly constant with respect to the exactly marginal couplings. The argument is general and applies even when the conformal symmetry is spontaneously broken on moduli spaces of vacua

A Path Integral for the Chiral-Form Partition Function

38 pages; v2: minor correctionsStarting from the recent action proposed by Sen [1,2], we evaluate the partition function of the compact chiral boson on a two-dimensional torus using a path-integral formulation. Crucially, we use a Wick-rotation procedure obtained from a complex deformation of the physical spacetime metric. This directly reproduces the expected result including general characteristics for the theta functions. We also present results for the chiral 2-form potential in six dimensions which can be readily extended to 4k+2 dimensions

Minimal Clinically Important Difference and Patient Acceptable Symptom State in Patients With Knee Osteoarthritis Treated With PRP Injection

Background: Although several injection-based treatments have been proposed to address knee osteoarthritis (OA), it is often difficult to understand the clinical relevance of the obtained results. The psychometric measures of minimal clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) were developed to better interpret study findings. Purpose: To establish the MCID and the PASS for the International Knee Documentation Committee (IKDC) Subjective score and the Knee injury and Osteoarthritis Outcome Score (KOOS) in patients treated with intra-articular platelet-rich plasma (PRP) injections for knee OA. Study Design: Case series; Level of evidence, 4. Methods: This study included 215 patients with knee OA (68% men, 32% women; age, 53.2 ± 11.3 years; body mass index, 26.8 ± 4.3 kg/m2) who underwent intra-articular PRP injections. Patients were assessed through the IKDC Subjective score and KOOS subscales, and the MCID and the PASS for both measures were independently calculated at 6 and 12 months post-injection. The MCID was calculated using the value equal to half of the standard deviation of the overall cohort improvement. The PASS was assessed using a 2-point scale (satisfied or not satisfied), with threshold values being detected through a receiver operating characteristic curve analysis and the Youden index to maximize the sensitivity and the specificity of the threshold values. Results: All scores improved significantly from baseline to 6 months and baseline to 12 months (P <.001 for all scores). All scores were stable from 6 to 12 months except for the KOOS Quality of Life subscale, which improved further (P =.033). For the IKDC, the MCID values were 8.6 and 8.5 points and the PASS scores were 59.7 and 62.1 at 6 and 12 months, respectively. Overall, the MCID and the PASS for all KOOS subscales remained constant at the 2 follow-up points. The percentage of patients who achieved the MCID and the PASS was higher than 85% at both 6 and 12 months post-injection. Conclusion: This study provided the MCID and PASS thresholds for the IKDC and KOOS scores in patients with knee OA treated with PRP injections. These psychometric measures may allow a better interpretation of the clinical relevance of injection-based treatment outcomes for knee OA

MTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids

Bronchial carcinoids (BCs) are rare neuroendocrine tumors that are still orphans of medical treatment. Human BC primary cultures may display resistance to everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), in terms of cell viability reduction. Our aim was to assess whether the novel dual phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor NVP-BEZ235 is effective in everolimus-resistant human BC tissues and cell lines. In addition, we searched for possible markers of the efficacy of mTOR inhibitors that may help in identifying the patients who may benefit from treatment with mTOR inhibitors, sparing them from ineffective therapy. We found that NVP-BEZ235 is twice as potent as everolimus in reducing cell viability and activating apoptosis in human BC tissues that display sensitivity to mTOR inhibitors, but is not effective in everolimus-resistant BC tissues and cell lines that bypass cyclin D1 downregulation and escape G0/G1 blockade. Rebound AKT activation was not observed in response to treatment with either mTOR inhibitor in the 'resistant' BC cells. In addition to total mTOR levels, putative markers of the sensitivity of BCs to mTOR inhibitors are represented by AKT, p70S6K (RPS6KB2), and ERK1/2 (MAPK3/1) protein levels. Finally, we validated these markers in an independent BC group. These data indicate that the dual PI3K/mTOR inhibitor NVP-BEZ235 is more potent than everolimus in reducing the proliferation of human BC cells. 'Resistant' cells display lower levels of mTOR, p70S6K, AKT, and ERK1/2, indicating that these proteins may be useful as predictive markers of resistance to mTOR and PI3K/mTOR inhibitors in human BCs. \ua9 2013 Society for Endocrinology

Staphylococcus aureus and Coagulase-Negative Staphylococci from Bloodstream Infections: Frequency of Occurrence and Antimicrobial Resistance, 2018–2021

Background: The abuse of antibiotics during the SARS-CoV-2 pandemic might have disrupted efforts to curb the further development and spread of the antimicrobial resistance of Staphylococcus aureus infection and Staphylococcus spp. coagulase-negative (CoNS) agents of nosocomial bloodstream infections (NBSIs). The purpose of our work was to study the resistance patterns of Staphylococcus aureus and CoNS through the analysis of blood cultures in hospitalized SARS-CoV-2-positive and SARS-CoV-2-negative patients (pts.). Materials and methods: During the period January 2018–June 2021, a retrospective case–control study was performed on blood cultures positive for Staphylococcus spp. detected in 177 adult pts. (≥18 years old) hospitalized for >48 hours at Sant’Elia Hospital, Caltanissetta. Results: Staphylococcus aureus was isolated in 33.9% of blood culture samples, and among CoNS, the most frequent strains were Staphylococcus capitis (18.6%) and Staphylococcus hominis (18.1%). Patients aged ≥ 65 years, with a greater number of males, comprised the SARS-CoV-2-negative pts. (71.8% vs. 52.2%, p = 0.0154). Among the SARS-CoV-2-positive patients, the significant resistance of Staphylococcus aureus was only observed for erythromycin (57.1%). The oxacillin resistance of Staphylococcus capitis was higher in SARS-CoV-2-positive than in negative pts. (90% and 78.3%, respectively). Comparing the two groups, we found an increase in resistance in SARS-CoV-2-negative patients for the following antibiotics: gentamicin for Staphylococcus aureus (p = 0.007), clindamycin and erythromycin (p = 0.012) for Staphylococcus hominis and oxacillin and rifampicin for Staphylococcus haemoliticus (p = 0.012). Conclusions: Our study confirms the relevance of oxacillin-resistant Staphylococcus aureus in being responsible for bloodstream infection and draws attention to highly oxacillin-resistant CoNS such as Staphylococcus capitis. The presence of resistant strains of CoNS in hospitals can be worrying, as it limits treatment options and worsens outcomes. The Infection Control Committee (ICC) recommends new treatment strategies to decrease colonization and infections. As part of the implementation of a bloodstream infection prevention program, the authors encourage the introduction of a report on the antimicrobial resistance of hospital bacteremia due to CoNS

Whale, whale, everywhere: increasing abundance of western South Atlantic humpback whales (Megaptera novaeangliae) in their wintering grounds

The western South Atlantic (WSA) humpback whale population inhabits the coast of Brazil during the breeding and calving season in winter and spring. This population was depleted to near extinction by whaling in the mid-twentieth century. Despite recent signs of recovery, increasing coastal and offshore development pose potential threats to these animals. Therefore, continuous monitoring is needed to assess population status and support conservation strategies. The aim of this work was to present ship-based line-transect estimates of abundance for humpback whales in their WSA breeding ground and to investigate potential changes in population size. Two cruises surveyed the coast of Brazil during August-September in 2008 and 2012. The area surveyed in 2008 corresponded to the currently recognized population breeding area; effort in 2012 was limited due to unfavorable weather conditions. WSA humpback whale population size in 2008 was estimated at 16,410 (CV = 0.228, 95% CI = 10,563–25,495) animals. In order to compare abundance between 2008 and 2012, estimates for the area between Salvador and Cabo Frio, which were consistently covered in the two years, were computed at 15,332 (CV = 0.243, 95% CI = 9,595–24,500) and 19,429 (CV = 0.101, 95% CI = 15,958–23,654) whales, respectively. The difference in the two estimates represents an increase of 26.7% in whale numbers in a 4-year period. The estimated abundance for 2008 is considered the most robust for the WSA humpback whale population because the ship survey conducted in that year minimized bias from various sources. Results presented here indicate that in 2008, the WSA humpback whale population was at least around 60% of its estimated pre-modern whaling abundance and that it may recover to its pre-exploitation size sooner than previously estimated.Publisher PDFPeer reviewe